Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody.
PDL Biopharma Inc (formerly Eos Biotechnology Inc) and Biogen Idec Inc are developing volociximab, an angiogenesis-inhibiting chimeric mAb that targets AAB1, a component protein of alpha5/beta1 integrin, for the potential treatment of solid tumors, including renal cell carcinoma. Two phase II clinical trials evaluating volociximab in solid tumors are underway. Volociximab is also under investigation for the treatment of age-related macular degeneration.
Kuwada
Scott K
SK
University of Utah, Huntsman Cancer Institute, Room 3243, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA. scott.kuwada@hsc.utah.edu
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D000075202:Contraindications; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy; D013329:Structure-Activity Relationship
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; C516631:volociximab